Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Incyte
INCY
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$63.02
-1.1
-1.72%
Last update: 10:29 AM
15 minutes delayed
Get Report
Comment
Incyte (INCY) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Incyte (NASDAQ:INCY) Stock
Incyte Stock (NASDAQ: INCY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, September 18, 2024
Incyte, Syndax Report Publication Of Data Fro...
Benzinga Newsdesk
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Vandana Singh
Truist Securities Downgrades Incyte to Hold, ...
Benzinga Newsdesk
Tuesday, September 17, 2024
JMP Securities Reiterates Market Perform on I...
Benzinga Newsdesk
Monday, September 16, 2024
Incyte shares are trading higher after B of A...
Benzinga Newsdesk
Guggenheim Maintains Buy on Incyte, Raises Pr...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Neutral on Incyt...
Benzinga Newsdesk
B of A Securities Maintains Neutral on Incyte...
Benzinga Newsdesk
Reported Saturday, Incyte Announced Results F...
Benzinga Newsdesk
Reported Saturday, Incyte Unveils Results For...
Benzinga Newsdesk
Monday, September 09, 2024
Cantor Fitzgerald Reiterates Neutral on Incyt...
Benzinga Newsdesk
Wednesday, September 04, 2024
Eli Lilly And EVA Pharma Entered Into An Agre...
Benzinga Newsdesk
Tuesday, September 03, 2024
Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Benzinga Insights
RBC Capital Reiterates Sector Perform on Incy...
Benzinga Newsdesk
Wednesday, August 21, 2024
Incyte To Present Late-Breaking Phase 3 Resul...
Benzinga Newsdesk
Friday, August 16, 2024
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
Vandana Singh
Thursday, August 15, 2024
Incyte Announces Topline Results From Study O...
Benzinga Newsdesk
Analyst Expectations For Incyte's Future
Benzinga Insights
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
Vandana Singh
RBC Capital Maintains Sector Perform on Incyt...
Benzinga Newsdesk
Wednesday, August 14, 2024
Incyte, Syndax Secure FDA Approval For Niktim...
Benzinga Newsdesk
FDA Approves Axatilimab-CSFR For Treatment Of...
Benzinga Newsdesk
Thursday, August 01, 2024
Deutsche Bank Maintains Hold on Incyte, Raise...
Benzinga Newsdesk
Wednesday, July 31, 2024
Citigroup Maintains Buy on Incyte, Raises Pri...
Benzinga Newsdesk
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
Vandana Singh
JP Morgan Maintains Neutral on Incyte, Raises...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on Incyt...
Benzinga Newsdesk
Incyte shares are trading lower. The company ...
Benzinga Newsdesk
B of A Securities Maintains Neutral on Incyte...
Benzinga Newsdesk
Tuesday, July 30, 2024
MacroGenics Achieves $100M In Milestones Rela...
Benzinga Newsdesk
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
Vandana Singh
Incyte shares are trading higher after the co...
Benzinga Newsdesk
Incyte Forecasts 2024 Jakafi Net Product Reve...
Benzinga Newsdesk
Incyte Q2 2024 Adj. EPS $(1.82) Misses $(1.55...
Benzinga Newsdesk
Friday, July 26, 2024
Analyst Ratings For Incyte
Benzinga Insights
Oppenheimer Maintains Outperform on Incyte, L...
Benzinga Newsdesk
Tuesday, July 09, 2024
S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
Piero Cingari
Tuesday, July 02, 2024
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Avi Kapoor
Mesoblast Soars 208% YTD on Positive Regulatory Updates
Zacks
Incyte shares are trading lower after BMO Cap...
Benzinga Newsdesk
BMO Capital Downgrades Incyte to Underperform...
Benzinga Newsdesk
Tuesday, June 18, 2024
Analyst Expectations For Incyte's Future
Benzinga Insights
Cantor Fitzgerald Reiterates Neutral on Incyt...
Benzinga Newsdesk
Thursday, June 13, 2024
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
Piero Cingari
Tuesday, June 11, 2024
Incyte Announces Preliminary Results Of Its M...
Benzinga Newsdesk
Tuesday, June 04, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Friday, May 24, 2024
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Piero Cingari
Thursday, May 23, 2024
9 Analysts Have This To Say About Incyte
Benzinga Insights
Deutsche Bank Initiates Coverage On Incyte wi...
Benzinga Newsdesk
Tuesday, May 21, 2024
Incyte Acquires 2 Downtown Wilmington Office ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch